UFP Technologies (UFPT) Q1 2026 earnings summary

Executive summary

• Net sales for Q1 2026 increased 4.1% year-over-year to $154.2 million, driven by 5.9% growth in medical sales and a strategic focus on high-growth MedTech segments, while non-medical sales declined 15% as automotive is phased out.

• Robotic surgery, patient services/support, and interventional/surgical segments grew 7%, 11%, and 15% respectively, partially offset by wound care declines due to customer inventory issues.

• Net income for Q1 2026 was $17.5 million, up 1.8% year-over-year from $17.2 million.

• Four major program launches are underway, with three customers requesting doubled capacity; these are expected to contribute significantly in the second half of the year.

• CEO transition planned for June, with Mitch Rock taking over and the outgoing CEO remaining as Executive Chair for a year.

Financial highlights

• Gross margin improved to 28.8% from 28.5% year-over-year, reflecting improved efficiencies despite labor inefficiencies at AJR.

• Adjusted operating margin was 16.7% of sales for Q1 2026.

• Adjusted earnings per diluted share were $2.48, up slightly year-over-year.

• SG&A expenses rose to $21.0 million (13.6% of sales), driven by back-office investments, equity compensation, and non-recurring legal expenses.

• Cash from operations was $3.2 million, lower than typical due to high working capital needs from strong March sales.

Outlook and guidance

• New program revenue growth expected to accelerate in the second half of 2026 as ramp-up continues, with four large programs contributing significantly.

• Non-medical business, especially automotive, is expected to remain weak as the company phases out of this market.

• Wound care segment expected to normalize after a three-quarter slowdown due to customer inventory, with new programs anticipated next year.

• Anticipated margin improvement from lower tariffs and potential vendor credits, though raw material costs remain volatile due to oil price fluctuations.

• Management remains bullish on future growth, citing a strong balance sheet, robust pipeline, and ramping new programs.